Radiotherapy Technique can be Important on Survival in Patients with Gastric Cancer Treated with Postoperative Chemoradiotherapy

OBJECTIVEThis study aims to investigate the clinical and pathological features of gastric carcinoma and to evaluatethe survival of the patients with gastric carcinoma receiving postoperative chemoradiotherapy.METHODSIn this study, two hundred and four patients who received postoperative chemoradiotherapy for gastriccancer in our clinic from 1999 to 2014 were evaluated retrospectively. Clinical prognostic factors affecting survival were studied.RESULTSThe median follow-up period was 30.52 months. Overall survival time was 80.47±5.04 months, and the5-year survival rate was 47.0±4.1%. Overall disease-free survival (DFS) time was 84.58±5.38 months. Alower number of dissected lymph nodes and a higher number of metastatic lymph nodes were found tobe related to increased risk of death and also a higher risk for recurrence. Stage 3 cancer was found tohave a higher recurrence risk than stage 1 and 2. Recipients of three-dimensional conformal radiotherapy (3DCRT) treatment had a lower risk of death compared to the patients that received 2D treatment.CONCLUSIONPostoperative chemoradiotherapy should be considered for all the patients with a high risk of recurrenceafter gastrectomy. In addition to the well-known prognostic factors, such as stage, lymph node metastasis, lymphatic dissection type, radiotherapy technique, was also found to be an important prognosticfactor in our study. These results suggest that there is a long-term survival benefit for the patients treatedwith 3DCRT.

PDF

___

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90.
2. Wong BC, Ching CK, Lam SK, Li ZL, Chen BW, Li YN, et al. Differential north to south gastric cancer-duodenal ulcer gradient in China. China Ulcer Study Group. J Gastroenterol Hepatol 1998;13(10):1050–7.
3. Steg PG, James SK, Atar D, LP Badano, CB Lundqvist, MA, Borger, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). European Heart Journal 2012;33: 2569–619.
4. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al., Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010;251:640–6.
5. Bollschweiler E, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Maruyama K, et al. Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer 1993;71:2918–25.
6. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric cancer 2013:16:1–27.
7. Joseph M Pepek, Junzo P Chino, Christopher G Willett, Manisha Palta, Dan G Blazer III, Douglas S Tyler, et al. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol 2013;8:6.
8. Pang, X, Wei W, Leng W, Chen Q, Xia H, Chen L, et al. Radiotherapy for gastric cancer: a systematic review and meta-analysis. Tumour Biol 2014;35(1):387–96.
9. Santiago JR, Munoz E, Marti M, Quintana S, Veloso E, Marco C. Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur J Surg Oncol 2005;31(1):59–66.
10.Ding YB, Chen GY, Xia JG, Zang XW, Yang HY, Yang L, et al. Correlation of tumor-positive ratio and number of perigastric lymph nodes with prognosis of patients with surgically-removed gastric carcinoma. World J Gastroenterol 2004;10(2):182–5.
11.Bando E, Yonemura Y, Taniguchi K, Fushida S, Fujimura T, Miwa K. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002;9(8):775–84.
12.Siewert, JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228(4):449–61.
13.Maruyama, K. The most important prognostic factors for gastric cancer patients: a study using univariate and multivariate analyses. Scandinavian Journal of Gastroenterology 1987:22:63–8.
14.Hyung, WJ, Lee JH, Choi SH, Min J.S., Noh S.H. Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol 2002;9(6):562–7.
15.Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med 2001;345(10):725–30.
16.Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990;19(6):1357–62.
17.Allgayer H, MM Heiss, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg 1997;84(12): 1651–64.
18.Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003;27(2):153–8.
19.Adachi Y, Shiraishi N, Suematsu T, Shiromizu A, Yamaguchi K, Kitano S. Most important lymph node information in gastric cancer: multivariate prognostic study. Ann Surg Oncol 2000;7(7):503–7.
20.Ersan Y, Erturk S, Cicek Y, Temiz M, Dirican A, Doğusoy G. Mide kanserli hastalarda klinikopatolojik prognostik faktörler. Cerrahpaşa Tıp Dergisi 2003;34(1).
21.Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol 2007;14(2):317–28.
22.Goto H, Tokunaga M, Sugisawa N, Tanizawa Y, Bando E, Kawamura T, et al. Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction. Gastric Cancer 2013;16(4):590–5.
23.Lavy R, Hershkovitz Y, Chikman B, Shapira Z, Poluksht N, Yarom N, et al. D1 versus D2 Gastrectomy for Gastric Adenocarcinoma. Isr Med Assoc J 2015; 17(12):735–8.
24.Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 2014;101(2):23–31.
25.Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Tatebe S, et al. Effect of age on prognosis in patients with gastric cancer. ANZ J Surg 2006;76(6):458–61.
26.Baeza MR, Giannini TO, Rivera SR, González P, González J, Vergara E, et al. Adjuvant radiochemotherapy in the treatment of completely resected, locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2001;50(3) 645–50.
27.Adas YG, Andrieu MN, Hicsonmez A, Atakul T, Dirican B, Aktas C, et al. Comparison of 2-dimensional and 3-dimensional conformal treatment plans in gastric cancer radiotherapy. Asian Pac J Cancer Prev 2014;15(17):7401–05.